Breast Biopsy Devices Market
Report ID: SQMIG35A3852
Report ID: SQMIG35A3852
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3852 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Breast Biopsy Devices Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.07 Billion in 2025 to USD 4.78 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).
Rising emphasis on early detection and the proliferation of advanced imaging technologies constitute the primary driver of the breast biopsy devices market, since they increase lesion detection and create demand for accurate tissue diagnosis. The market encompasses devices used to obtain breast tissue via image-guided core needle biopsy, vacuum-assisted biopsy and stereotactic or MRI-guided systems and this market is significant because timely minimally invasive diagnosis reduces unnecessary surgeries and improves patient outcomes. Over the past two decades the field has evolved from predominantly surgical excision toward outpatient percutaneous procedures, with innovations such as vacuum-assisted sampling and real-time imaging improving accuracy and workflow.
The central growth catalyst is tighter integration of imaging modalities with percutaneous biopsy devices, because improved lesion localization drives higher diagnostic yield and reduces sampling errors which in turn expands clinician confidence and procedural adoption. When ultrasound or MRI is coupled to vacuum-assisted or core needle systems operators can target nonpalpable lesions during outpatient visits and thereby avoid hospital admissions and surgical excision, leading to cost savings and faster treatment decisions. As a result vendors gain opportunities to develop AI augmented guidance, single-use disposable kits for infection control and portable platforms tailored to emerging markets where screening programmes are expanding.
How is AI improving diagnostic accuracy in the breast biopsy devices market?
AI is improving diagnostic accuracy in the breast biopsy devices industry by strengthening image interpretation, lesion characterization and procedural guidance. Machine learning models flag subtle features and provide second reads that help clinicians select the most suspicious targets. Integration with ultrasound MRI and tomosynthesis creates clearer context for sampling and reduces ambiguity during needle placement. The current market shows growing adoption of validated AI tools within imaging and biopsy workflows as manufacturers emphasize clinical evidence and workflow gains. Real world instances include AI assisted triage that prioritizes challenging cases and decision support that increases clinician confidence during image guided biopsy.
Perimeter Medical Imaging AI in March 2026, announced FDA approval and commercial rollout of its Claire AI enabled imaging system, which provides real time AI assisted margin assessment during surgery and supports market efficiency by reducing repeat procedures and improving diagnostic confidence.
Market snapshot - (2026-2033)
Global Market Size
USD 2.9 Billion
Largest Segment
Needle-Based Biopsy Devices
Fastest Growth
Localization Devices
Growth Rate
5.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global breast biopsy devices market is segmented by product type, guidance technique, procedure type, end user and region. Based on product type, the market is segmented into Needle-Based Biopsy Devices, Surgical Biopsy Devices, Localization Devices and Accessories & Consumables. Based on guidance technique, the market is segmented into Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy and Others. Based on procedure type, the market is segmented into Minimally Invasive Biopsy and Surgical Biopsy. Based on end user, the market is segmented into Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Needle based biopsy devices segment dominates with large global breast biopsy devices market share because their minimally invasive profile aligns with clinician preference for lower morbidity procedures, enabling faster patient throughput and outpatient management. Familiarity among radiologists and surgeons, broad compatibility with imaging guidance, and ongoing design improvements in needle technology increase diagnostic yield and procedural efficiency, driving purchasing decisions across hospitals and diagnostic centers and reinforcing established care pathways. These factors create a virtuous cycle of adoption and incremental innovation.
As pr global breast biopsy devices market outlook, localization devices are emerging as the fastest growing area due to advances in marker technologies and integration with imaging workflows. Emphasis on precise lesion localization before surgery, adoption of wireless and magnetic seeds, and demand for streamlined preoperative pathways drive investment and create opportunities for new devices and service partnerships.
As pr global breast biopsy devices market forecast, MRI guided biopsy segment leads because its capability to visualize lesions not seen on other modalities makes it essential for complex diagnostic workflows and high risk surveillance. The need for MRI compatible instruments and specialized disposables has driven manufacturers to invest in dedicated device platforms, integrated imaging procedures and center expertise, elevating standard of care and encouraging procurement at advanced diagnostic facilities. This focus supports premium pricing and ongoing clinical research that reinforces leadership.
As pr global breast biopsy devices market analysis, ultrasound guided biopsy is the most rapidly expanding approach due to real time imaging, portability and lower procedural costs that broaden point of care access. Improvements in probe technology and needle visualization raise diagnostic confidence, fueling outpatient adoption and new product and service opportunities for manufacturers and clinical providers.
To get detailed segments analysis, Request a Free Sample Report
North America leads the global breast biopsy devices market due to its robust clinical infrastructure, concentrated innovation, and advantageous reimbursement policies that promote adoption. Elevated screening awareness and established diagnostic protocols promote early identification and the regular application of less invasive biopsy techniques. A strong network of device manufacturers, contract research organizations, and academic institutions facilitates swift product development and clinical validation. Regulatory procedures, however stringent, are comprehensively understood by industry stakeholders, facilitating more seamless market entrance. Intense investor interest and integrated hospital networks expedite the acquisition and distribution of novel devices. Comprehensive clinician training programs and interdisciplinary care models facilitate integration into routine practice, while proactive patient advocacy and awareness initiatives stimulate demand for accurate diagnostic alternatives.
As pr global breast biopsy devices market regional outlook, United States benefits from dense clinical research networks, strong ties between industry and academic medical centers, and a well established reimbursement ecosystem that supports adoption. High clinician familiarity with image guided techniques and broad availability of advanced imaging contribute to routine use. Active venture investment and streamlined commercial channels enable rapid distribution of new devices, while consolidated hospital systems facilitate standardized procurement and training.
As pr global breast biopsy devices market regional forecast, Canada is characterized by provincially organized healthcare delivery that emphasizes equitable access and integration of based diagnostic services. Urban centers serve as hubs for technology adoption, supported by collaborative national procurement strategies and partnerships with manufacturers. Emphasis on clinician training, patient centered care pathways, and referral networks enhances uptake. Investment in outreach and diagnostic pathways helps extend access beyond major centers, supporting standardized practice patterns.
As pr global breast biopsy devices industry analysis, Europe is seeing swift growth, propelled by legislative support for early detection, the development of diagnostic infrastructure, and the proactive clinical adoption of advanced image-guided and minimally invasive technologies. Health institutions in several markets are emphasizing uniform diagnostic routes and coordinated procurement to promote investment in interoperable devices. Robust clinical data produced by academic institutions and regional registries bolsters physician trust, while international collaboration and knowledge sharing expedite the dissemination of best practices. A developed medtech manufacturing sector, supported by targeted regulatory interaction and pathway enhancement, facilitates the expedited launch and commercialization of innovative devices. These variables jointly enhance Europe from a fragmented landscape to a more integrated and innovation-friendly market environment, hence improving patient access.
Germany is anchored by a strong medtech manufacturing base and hospital network that support adoption of advanced biopsy solutions. Collaboration between clinical research centers and industry accelerates device validation, while reimbursement pathways facilitate procurement. Centers of excellence provide training and protocol standardization, and regional purchasing consortia scale distribution. Institutional expertise and manufacturing capability underpin Germany leading role in European device innovation and clinical deployment leadership.
United Kingdom is experiencing rapid adoption driven by modernization of diagnostic pathways, strong clinician engagement, and participation from private providers and public health services. Widespread use of image guided techniques and integration with digital imaging platforms improves diagnostic accuracy and workflow. Investment in training programs and collaborative pilots with manufacturers supports clinical assimilation. Streamlined national procurement frameworks and focused policy support create a dynamic environment.
France is emerging as stakeholders prioritize improved diagnostic pathways and greater access to minimally invasive procedures. Regional reference centers and academic hospitals drive clinical evaluation and adoption, while investment supports manufacturing and collaborative research. Progressive reimbursement adjustments and payer engagement encourage technology uptake. Emphasis on multidisciplinary care models and patient centered care enhances acceptance among clinicians, facilitating expansion from adoption corridors toward broader clinical integration.
Asia Pacific region is enhancing its standing in the breast biopsy devices market by expanding clinical capacity, strategically investing in diagnostic imaging, and developing local manufacturing capabilities. Regional politicians and healthcare providers are concentrating on developing organized screening and referral systems that enhance the demand for dependable, less invasive biopsy technologies. Technology transfer and collaborations between international suppliers and local enterprises facilitate adaption to regional healthcare workflows and financial frameworks. The growing focus on clinical trials, physician education, and the use of new imaging techniques improves local evidence production and clinician assurance. Collectively, these measures are diminishing obstacles to acceptance, facilitating broader deployment across various healthcare environments and enhancing Asia Pacific's status as a progressively crucial area for device development and commercialization.
Japan is shaped by advanced imaging infrastructure, clinical research networks, and a mature medtech industry that supports local development and adaptation of biopsy technologies. Clinician proficiency in image guided procedures and focused training programs drive adoption. Collaboration between hospitals and manufacturers accelerates product refinement, while regulatory processes emphasize evidence generation. Patient pathways and integration with diagnostic services enhance acceptance and use across specialty centers nationally.
South Korea is driven by advanced hospital systems, adoption of digital imaging platforms, and collaboration between domestic manufacturers and global suppliers. Clinical willingness to trial novel devices and tertiary centers facilitate integration of minimally invasive biopsy techniques. Government and private sector initiatives support clinician training and evidence generation, while efficient regulatory pathways enable timely evaluation. Export orientation and quality focus strengthen domestic capability and competitiveness.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advances In Imaging Integration
Growing Awareness and screening
High Procedure Costs
Regulatory Approval Challenges
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in the global breast biopsy devices industry is driven by consolidation and technology differentiation, with incumbents using acquisitions and targeted partnerships to secure imaging and marker portfolios, and rivals pursuing AI and robotics to capture niche clinical workflows. Examples include Hologic acquiring Somatex to expand marker offerings, Perimeter advancing AI enabled OCT and clinical partnerships, and recent startup clearances intensifying competition.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global breast biopsy devices market growth is being propelled by a rising emphasis on early detection and the proliferation of advanced imaging technologies that increase lesion detection and demand for accurate tissue diagnosis. A second driver is tighter integration of imaging modalities with percutaneous biopsy systems and growing adoption of AI-enabled guidance, which enhances targeting and workflow efficiency. However high procedure costs and associated consumable expenses restrain uptake in resource-limited settings. North America remains the dominant region supported by strong infrastructure and reimbursement, while needle-based biopsy devices are the leading segment due to their minimally invasive profile, clinician familiarity and outpatient workflow advantages. The global breast biopsy devices trend is driven by the rising prevalence of breast cancer, increasing participation in screening programs, and growing demand for early and accurate diagnosis.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.9 Billion |
| Market size value in 2033 | USD 4.78 Billion |
| Growth Rate | 5.7% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Breast Biopsy Devices Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Breast Biopsy Devices Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Breast Biopsy Devices Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Breast Biopsy Devices Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Breast Biopsy Devices Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.07 Billion in 2025 to USD 4.78 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).
Competitive landscape in the global breast biopsy devices market is driven by consolidation and technology differentiation, with incumbents using acquisitions and targeted partnerships to secure imaging and marker portfolios, and rivals pursuing AI and robotics to capture niche clinical workflows. Examples include Hologic acquiring Somatex to expand marker offerings, Perimeter advancing AI enabled OCT and clinical partnerships, and recent startup clearances intensifying competition. 'Hologic, Inc.', 'Becton, Dickinson and Company (BD)', 'Danaher Corporation', 'Siemens Healthineers AG', 'Koninklijke Philips N.V.', 'GE HealthCare Technologies Inc.', 'Argon Medical Devices, Inc.', 'Cook Medical', 'Merit Medical Systems, Inc.', 'Boston Scientific Corporation', 'Cardinal Health, Inc.', 'Olympus Corporation', 'Fujifilm Holdings Corporation', 'Devicor Medical Products, Inc.', 'Stryker Corporation', 'Medtronic plc', 'B. Braun Melsungen AG', 'Thermo Fisher Scientific Inc.', 'Zimmer Biomet Holdings, Inc.', 'Intuitive Surgical, Inc.'
Integration of advanced imaging modalities with biopsy devices enhances lesion localization, enabling more precise sampling and reducing diagnostic uncertainty. Clinicians are more likely to adopt systems that streamline workflow between imaging and intervention, which supports broader uptake across care settings. Improved image guidance fosters clinician confidence in obtaining representative tissue and facilitates multidisciplinary decision making, thereby strengthening demand for modern biopsy solutions. The perceived value from clearer visualization and coordinated procedures encourages investment by hospitals and imaging centers seeking to improve patient care pathways.
Minimally Invasive Procedure Adoption: Growing preference for less invasive biopsy techniques is reshaping clinical pathways. Clinicians favor devices that enable precise tissue sampling with minimal disruption, supporting quicker recovery and improved patient experience. Suppliers emphasize ergonomic designs, compatibility with advanced imaging, and streamlined disposables to facilitate outpatient care. Adoption is driven by multidisciplinary collaboration, training programs, and payer recognition of value tied to reduced complications. Market focus is shifting toward integrated solutions that simplify workflows, improve diagnostic confidence, and support access across care settings.
Why does North America Dominate the Global Breast Biopsy Devices Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
